Protagonist Therapeutics Price to Book Ratio 2015-2022 | PTGX

Historical price to book ratio values for Protagonist Therapeutics (PTGX) over the last 10 years. The current price to book ratio for Protagonist Therapeutics as of July 01, 2022 is 1.27.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Protagonist Therapeutics Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2022-07-01 7.86 1.26
2022-03-31 23.68 $6.22 3.81
2021-12-31 34.20 $6.27 5.45
2021-09-30 17.72 $6.92 2.56
2021-06-30 44.88 $7.52 5.97
2021-03-31 25.90 $5.90 4.39
2020-12-31 20.16 $6.39 3.15
2020-09-30 19.55 $4.54 4.30
2020-06-30 17.66 $4.55 3.88
2020-03-31 7.06 $2.28 3.09
2019-12-31 7.05 $2.94 2.40
2019-09-30 12.01 $3.51 3.43
2019-06-30 12.11 $3.38 3.59
2019-03-31 12.57 $4.31 2.92
2018-12-31 6.73 $4.85 1.39
2018-09-30 10.29 $5.14 2.00
2018-06-30 6.72 $5.07 1.32
2018-03-31 8.59 $5.42 1.59
2017-12-31 20.80 $5.72 3.64
2017-09-30 17.67 $3.41 5.18
2017-06-30 11.31 $3.61 3.13
2017-03-31 12.81 $4.45 2.88
2016-12-31 21.99 $5.24 4.20
2016-09-30 21.13 $5.83 3.62
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.382B $0.027B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00